sulbactam Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
beta-lactamase inhibitors 2492 68373-14-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • sulbactam
  • penicillanic acid dioxide
  • sulbactam sodium
A beta-lactamase inhibitor with very weak antibacterial action. The compound prevents antibiotic destruction of beta-lactam antibiotics by inhibiting beta-lactamases, thus extending their spectrum activity. Combinations of sulbactam with beta-lactam antibiotics have been used successfully for the therapy of infections caused by organisms resistant to the antibiotic alone.
  • Molecular weight: 233.24
  • Formula: C8H11NO5S
  • CLOGP: 0.31
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 1
  • TPSA: 91.75
  • ALOGS: -0.68
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 g P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 285.97 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.32 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.62 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 31, 1986 FDA PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Enterocolitis haemorrhagic 88.78 20.18 23 5436 1517 46679086
Pyrexia 71.88 20.18 138 5321 348664 46331939
Hepatic function abnormal 63.02 20.18 43 5416 34378 46646225
Drug eruption 62.70 20.18 36 5423 21293 46659310
Klebsiella infection 59.10 20.18 24 5435 6638 46673965
Enterococcal infection 44.81 20.18 20 5439 6967 46673636
Renal impairment 44.56 20.18 49 5410 74323 46606280
Lemierre syndrome 42.59 20.18 8 5451 115 46680488
Disseminated intravascular coagulation 37.78 20.18 25 5434 18980 46661623
Infective aneurysm 37.58 20.18 9 5450 429 46680174
Linear IgA disease 35.76 20.18 11 5448 1350 46679253
Pneumonia aspiration 34.50 20.18 29 5430 31576 46649027
Toxic epidermal necrolysis 34.19 20.18 25 5434 22253 46658350
Fatigue 30.10 20.18 17 5442 608680 46071923
Culture stool positive 29.75 20.18 7 5452 309 46680294
Interstitial lung disease 29.65 20.18 34 5425 53915 46626688
Eosinophilic pneumonia acute 28.75 20.18 7 5452 358 46680245
Pathogen resistance 28.49 20.18 14 5445 6046 46674557
Crystal nephropathy 27.45 20.18 8 5451 817 46679786
Multiple organ dysfunction syndrome 27.43 20.18 32 5427 51678 46628925
Red blood cells urine positive 25.22 20.18 10 5449 2597 46678006
Arthralgia 24.99 20.18 6 5453 364597 46316006
Sepsis 24.45 20.18 51 5408 135963 46544640
Pseudomembranous colitis 23.25 20.18 10 5449 3185 46677418
Acute generalised exanthematous pustulosis 22.73 20.18 14 5445 9391 46671212
Proteus infection 22.57 20.18 7 5452 883 46679720
Pneumonia 22.36 20.18 95 5364 376225 46304378
Klebsiella test positive 21.79 20.18 7 5452 990 46679613
Acute disseminated encephalomyelitis 21.61 20.18 5 5454 205 46680398
Implant site hypersensitivity 21.46 20.18 4 5455 55 46680548
Systemic candida 21.39 20.18 9 5450 2718 46677885
Neuromuscular block prolonged 21.33 20.18 6 5453 540 46680063
Shock haemorrhagic 21.26 20.18 13 5446 8611 46671992
Drug resistance 21.17 20.18 17 5442 17351 46663252
Lymphocyte count decreased 21.01 20.18 20 5439 25569 46655034
Platelet count decreased 20.96 20.18 40 5419 99984 46580619
Anaphylactic shock 20.88 20.18 18 5441 20256 46660347
Rash morbilliform 20.54 20.18 9 5450 3000 46677603

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatic function abnormal 114.88 17.69 88 6956 41857 29903577
Enterocolitis haemorrhagic 74.08 17.69 21 7023 956 29944478
Pneumonia 62.66 17.69 196 6848 334110 29611324
Cardiac septal defect 54.74 17.69 12 7032 185 29945249
Interstitial lung disease 54.66 17.69 69 6975 60128 29885306
Pneumonia aspiration 54.30 17.69 55 6989 37725 29907709
Pathogen resistance 50.90 17.69 29 7015 8381 29937053
Hangover 50.59 17.69 16 7028 1062 29944372
Kidney duplex 47.68 17.69 12 7032 344 29945090
Pyrexia 43.83 17.69 160 6884 294329 29651105
Rash 39.96 17.69 117 6927 191772 29753662
Incision site pain 37.39 17.69 15 7029 1989 29943445
Drug eruption 35.72 17.69 31 7013 17495 29927939
C-reactive protein increased 35.02 17.69 47 6997 43426 29902008
Clostridium test positive 33.62 17.69 14 7030 2042 29943392
Wound dehiscence 33.02 17.69 16 7028 3325 29942109
Multiple-drug resistance 31.86 17.69 15 7029 2926 29942508
Pseudomembranous colitis 29.15 17.69 14 7030 2854 29942580
Lymphocyte count decreased 27.83 17.69 28 7016 19027 29926407
Klebsiella infection 26.99 17.69 18 7026 6869 29938565
Liver disorder 26.83 17.69 34 7010 29688 29915746
Rebound effect 26.78 17.69 11 7033 1550 29943884
Death 26.60 17.69 27 7017 357256 29588178
Acute generalised exanthematous pustulosis 26.49 17.69 17 7027 6081 29939353
Pneumonia bacterial 26.28 17.69 20 7024 9383 29936051
Megacolon 26.14 17.69 11 7033 1646 29943788
Enterococcus test positive 25.45 17.69 9 7035 843 29944591
Stenotrophomonas test positive 24.72 17.69 7 7037 317 29945117
Respiratory failure 24.46 17.69 65 6979 100577 29844857
Toxic epidermal necrolysis 23.73 17.69 25 7019 17915 29927519
Alanine aminotransferase increased 23.38 17.69 53 6991 74223 29871211
Red blood cells urine positive 23.08 17.69 10 7034 1607 29943827
Pulmonary alveolar haemorrhage 22.94 17.69 16 7028 6565 29938869
Coagulopathy 21.38 17.69 24 7020 18463 29926971
Platelet count decreased 21.33 17.69 64 6980 106065 29839369
Paradoxical drug reaction 21.16 17.69 11 7033 2651 29942783
Renal impairment 21.08 17.69 55 6989 84129 29861305
Aspartate aminotransferase increased 20.79 17.69 46 6998 63376 29882058
White blood cell count increased 20.65 17.69 35 7009 39638 29905796
Drug-induced liver injury 20.25 17.69 25 7019 21249 29924185
Conjunctivitis 20.15 17.69 16 7028 7984 29937450
Protein urine present 19.97 17.69 13 7031 4762 29940672
Fall 19.83 17.69 9 7035 181863 29763571
Septic shock 19.59 17.69 45 6999 63562 29881872
Disseminated intravascular coagulation 19.43 17.69 25 7019 22146 29923288
Toxicity to various agents 18.95 17.69 9 7035 177174 29768260
Nutritional condition abnormal 18.21 17.69 6 7038 454 29944980
Blood creatine phosphokinase increased 18.13 17.69 35 7009 43813 29901621
Blood urea increased 18.10 17.69 29 7015 31352 29914082

Pharmacologic Action:

SourceCodeDescription
ATC J01CG01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
BETA-LACTAM ANTIBACTERIALS, PENICILLINS
Beta-lactamase inhibitors
FDA MoA N0000000202 beta Lactamase Inhibitors
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D065093 beta-Lactamase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
FDA EPC N0000175930 beta Lactamase Inhibitor

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Infection of skin AND/OR subcutaneous tissue indication 19824006
Infection due to Escherichia coli indication 71057007
Rhinoscleroma indication 72409005 DOID:11336
Cholangitis indication 82403002 DOID:9446
Female genital tract infection indication 125585007
Infectious disease of abdomen indication 128070006
Infection due to Enterobacteriaceae indication 128945009
Bacterial peritonitis indication 197171003
Infection due to Staphylococcus aureus indication 406602003
E. Coli Gynecological Infections indication
Klebsiella Pneumoniae Peritonitis indication
E. Coli Peritonitis indication
Skin and Skin Structure Bacteroides Fragilis Infection indication
Bacteroides Gynecological Infections indication
Inflammatory Disease of Female Pelvic Organs indication
Skin and Skin Structure Acinetobacter Infection indication
Bacteroides Peritonitis indication
Skin and Skin Structure Proteus Infection indication
Intra-Abdominal E. Coli Abscess indication
Streptococcal meningitis off-label use 4510004 DOID:11574
Pyrexia of unknown origin off-label use 7520000
Bacterial pneumonia off-label use 53084003 DOID:874
Infection of bone off-label use 111253001
Meningococcal meningitis off-label use 192644005
Sepsis of the newborn off-label use 206376005
Human bite - wound off-label use 262555007
Diverticulitis of gastrointestinal tract off-label use 271366000
Neonatal meningitis off-label use 276674008
Dog bite - wound off-label use 283734005
Cat bite - wound off-label use 283782004
Infective otitis media off-label use 312218008
Diabetic Foot Infection off-label use
Kidney disease contraindication 90708001 DOID:557
Infectious mononucleosis contraindication 271558008 DOID:8568
Pseudomembranous enterocolitis contraindication 397683000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.1 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Serine beta-lactamase-like protein LACTB, mitochondrial Enzyme IC50 5.01 WOMBAT-PK
Beta-lactamase TEM Enzyme INHIBITOR Ki 6.10 CHEMBL CHEMBL
Beta-lactamase Enzyme IC50 5.62 CHEMBL
Beta-lactamase Enzyme IC50 6 CHEMBL
Beta-lactamase Enzyme IC50 5.19 CHEMBL
Beta-lactamase Enzyme IC50 5.95 CHEMBL
Beta-lactamase Enzyme IC50 5.11 CHEMBL
Carbapenem-hydrolizing beta-lactamase SFC-1 Enzyme IC50 4.64 CHEMBL
ADC-18 protein Unclassified IC50 4.93 CHEMBL
Beta-lactamase Enzyme IC50 4.18 CHEMBL
Beta-lactamase Enzyme IC50 4.57 CHEMBL
Beta-lactamase 1 Unclassified IC50 4.60 CHEMBL
Beta-lactamase Enzyme IC50 5.40 CHEMBL
Beta-lactamase Enzyme IC50 7.12 CHEMBL
Beta-lactamase Enzyme IC50 5.21 CHEMBL
Beta-lactamase OXA-1 Enzyme IC50 4.66 CHEMBL
Class D beta-lactamase Unclassified IC50 4.92 CHEMBL
Beta-lactamase TEM Enzyme Ki 6.10 WOMBAT-PK
Beta-lactamase GES-13 Enzyme IC50 6.43 CHEMBL

External reference:

IDSource
4019937 VUID
N0000148022 NUI
D02223 KEGG_DRUG
69388-84-7 SECONDARY_CAS_RN
4019381 VANDF
4019937 VANDF
C0038665 UMLSCUI
CHEBI:9321 CHEBI
0RN PDB_CHEM_ID
CHEMBL403 ChEMBL_ID
CHEMBL1200944 ChEMBL_ID
D013407 MESH_DESCRIPTOR_UI
4845 INN_ID
DB09324 DRUGBANK_ID
S4TF6I2330 UNII
130313 PUBCHEM_CID
10769 IUPHAR_LIGAND_ID
10167 RXNORM
5520 MMSL
d04403 MMSL
002811 NDDF
002812 NDDF
398916003 SNOMEDCT_US
412516007 SNOMEDCT_US
96008003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
UNULLSYN HUMAN PRESCRIPTION DRUG LABEL 2 0049-0013 INJECTION, POWDER, FOR SOLUTION 0.50 g INTRAMUSCULAR NDA 26 sections
UNULLSYN HUMAN PRESCRIPTION DRUG LABEL 2 0049-0014 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR NDA 26 sections
UNULLSYN HUMAN PRESCRIPTION DRUG LABEL 2 0049-0024 INJECTION, POWDER, FOR SOLUTION 50 mg INTRAMUSCULAR NDA 25 sections
UNULLSYN HUMAN PRESCRIPTION DRUG LABEL 2 0049-0031 INJECTION, POWDER, FOR SOLUTION 0.50 g INTRAMUSCULAR ANDA 26 sections
UNULLSYN HUMAN PRESCRIPTION DRUG LABEL 2 0049-0032 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 26 sections
Ampicillin and Sulbactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-2689 INJECTION, POWDER, FOR SOLUTION 0.50 g INTRAVENOUS ANDA 25 sections
Ampicillin and Sulbactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-2987 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 25 sections
Ampicillin and Sulbactam HUMAN PRESCRIPTION DRUG LABEL 2 0641-6116 INJECTION, POWDER, FOR SOLUTION 0.50 g INTRAVENOUS ANDA 24 sections
Ampicillin and Sulbactam HUMAN PRESCRIPTION DRUG LABEL 2 0641-6117 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 24 sections
Ampicillin and Sulbactam HUMAN PRESCRIPTION DRUG LABEL 2 0641-6118 INJECTION, POWDER, FOR SOLUTION 50 mg INTRAVENOUS ANDA 24 sections
Ampicillin and Sulbactam HUMAN PRESCRIPTION DRUG LABEL 2 0641-6119 INJECTION, POWDER, FOR SOLUTION 0.50 g INTRAVENOUS ANDA 25 sections
Ampicillin and Sulbactam HUMAN PRESCRIPTION DRUG LABEL 2 0641-6120 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 25 sections
Ampicillin and Sulbactam HUMAN PRESCRIPTION DRUG LABEL 2 0641-6121 INJECTION, POWDER, FOR SOLUTION 50 mg INTRAVENOUS ANDA 24 sections
Ampicillin and Sulbactam HUMAN PRESCRIPTION DRUG LABEL 2 0641-6122 INJECTION, POWDER, FOR SOLUTION 125 mg INTRAVENOUS ANDA 25 sections
Ampicillin and Sulbactam HUMAN PRESCRIPTION DRUG LABEL 2 0641-6123 INJECTION, POWDER, FOR SOLUTION 125 mg INTRAVENOUS ANDA 25 sections
ampicillin and sulbactam HUMAN PRESCRIPTION DRUG LABEL 2 25021-142 INJECTION, POWDER, FOR SOLUTION 0.50 g INTRAVENOUS ANDA 25 sections
ampicillin and sulbactam HUMAN PRESCRIPTION DRUG LABEL 2 25021-143 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 25 sections
ampicillin and sulbactam HUMAN PRESCRIPTION DRUG LABEL 2 25021-144 INJECTION, POWDER, FOR SOLUTION 50 mg INTRAVENOUS ANDA 25 sections
Ampicillin and Sulbactam HUMAN PRESCRIPTION DRUG LABEL 2 36000-094 INJECTION, POWDER, FOR SOLUTION 0.50 g INTRAVENOUS ANDA 26 sections
Ampicillin and Sulbactam HUMAN PRESCRIPTION DRUG LABEL 2 36000-095 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 26 sections
Ampicillin and Sulbactam HUMAN PRESCRIPTION DRUG LABEL 2 44567-210 INJECTION, POWDER, FOR SOLUTION 0.50 g INTRAVENOUS ANDA 23 sections
Ampicillin and Sulbactam HUMAN PRESCRIPTION DRUG LABEL 2 44567-211 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 23 sections
Ampicillin and Sulbactam HUMAN PRESCRIPTION DRUG LABEL 2 44567-212 INJECTION, POWDER, FOR SOLUTION 5 g INTRAVENOUS ANDA 21 sections
Ampicillin and Sulbactam Human Prescription Drug Label 2 55150-116 INJECTION, POWDER, FOR SOLUTION 0.50 g INTRAMUSCULAR ANDA 23 sections
Ampicillin and Sulbactam Human Prescription Drug Label 2 55150-117 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 23 sections
Ampicillin and Sulbactam Human Prescription Drug Label 2 55150-118 INJECTION, POWDER, FOR SOLUTION 50 mg INTRAVENOUS ANDA 23 sections
Ampicillin and Sulbactam Human Prescription Drug Label 2 55150-178 INJECTION, POWDER, FOR SOLUTION 0.50 g INTRAVENOUS ANDA 22 sections
Ampicillin and Sulbactam Human Prescription Drug Label 2 55150-179 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 22 sections
ampicillin and sulbactam HUMAN PRESCRIPTION DRUG LABEL 2 66794-206 INJECTION, POWDER, FOR SOLUTION 0.50 g INTRAVENOUS ANDA 13 sections
ampicillin and sulbactam HUMAN PRESCRIPTION DRUG LABEL 2 66794-207 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 13 sections